Protagonist Therapeutics PTGX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAccountsPayableAndAccruedLiabilities.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's accrued expenses?
- Protagonist Therapeutics (PTGX) reported accrued expenses of $17.49M in Q1 2026.
- How has Protagonist Therapeutics's accrued expenses changed year-over-year?
- Protagonist Therapeutics's accrued expenses increased by 47.7% year-over-year, from $11.84M to $17.49M.
- What is the long-term trend for Protagonist Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Protagonist Therapeutics's accrued expenses has grown at a 8.9% compound annual growth rate (CAGR), from $18.5M to $28.27M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.